|
|
Article: GlaxoSmithKline Consumer Healthcare to Promote Benefit of Weight Loss With Xenical(R) (Orlistat) for Preventing Type 2 Diabetes; Promotion Agreement with Roche Aimed at Supporting Xenical as a Powerful Tool Against the Consequences of Excess Weight.
- Article from:
- PR Newswire
- Article date:
- April 12, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PITTSBURGH, April 12 /PRNewswire/ -- GlaxoSmithKline Consumer Healthcare (GSK Consumer Healthcare) announced today an agreement with Roche to promote the leading prescription weight loss medication Xenical(R) (orlistat) to physicians nationwide. The company's efforts will focus on the recent FDA- approved label change, based on the landmark four-year XENDOS study, indicating that weight loss with Xenical reduces the risk of developing type 2 diabetes in obese patients with impaired glucose tolerance.
"Extensive research shows that excess weight is a primary risk factor for the development of type 2 diabetes, which we know leads to an increase in morbidity and ...